Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05983133 · ClinicalTrials.gov registry record · Phase 1

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Active
Registry status
Phase 1
Development phase
65
Enrollment target
20
Study locations

NCT05983133: Active Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

NCT05983133 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 65 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05983133, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
65 participants
Enrollment target
20
Study locations

Study Summary

This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.

Primary Outcome

An AE is any untoward medical occurrence in a clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention

Conditions Studied

Carcinoma, Non-Small Cell Lung Pancreatic Ductal Adenocarcinoma Colorectal Neoplasms Squamous Cell Carcinoma of the Head and Neck

Interventions

  • DRUG PF-08046052

Study Locations (20)

California

  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA Hematology/Oncology - Los Angeles
  • Santa Monica UCLA Medical Center & Orthopaedic Hospital - Santa Monica
  • UCLA Hematology/Oncology - Santa Monica - Santa Monica

Florida

  • Moffitt Cancer Center McKinley Hospital - Tampa
  • Moffitt Cancer Center - Tampa

Michigan

  • Karmanos Cancer Institute - Detroit
  • Karmanos Cancer Institute Weisberg Cancer Treatment Center - Farmington Hills

New Jersey

  • Hackensack University Medical Center - Hackensack
  • John Theurer Cancer Center at Hackensack University Medical Center - Hackensack

North Carolina

  • Atrium Health Wake forest Baptist - Winston-Salem
  • Wake Forest Baptist Medical Center / Wake Forest University - Winston-Salem

Oregon

  • Providence Cancer Institute Franz Clinic - Portland
  • Providence Portland Medical Center - Portland

Texas

  • MD Anderson Cancer Center - University of Texas - Houston
  • The University of Texas MD Anderson Cancer Center - Houston

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2023-11-14
Est. Completion 2026-08-14
Phase Phase 1
Seagen, a wholly owned subsidiary of Pfizer

28 total trials

What the registry record for NCT05983133 still lists

NCT05983133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (80% lower).

The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which PF-08046052 is the first listed.

NCT05983133 names 20 study sites across 11 states, led by California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT05983133 about?

NCT05983133 is a clinical study titled "A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors". This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed ...

What is the current status of trial NCT05983133?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2023-11-14. Estimated completion is 2026-08-14.

What conditions does trial NCT05983133 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Pancreatic Ductal Adenocarcinoma, Colorectal Neoplasms, Squamous Cell Carcinoma of the Head and Neck.

What interventions are being tested in trial NCT05983133?

The interventions under investigation include: PF-08046052 (DRUG).

Who is sponsoring clinical trial NCT05983133?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05983133 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05983133's enrollment target sits among peer trials

65 87th of 130 higher than 44 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05983133, the US trial registry maintained by the National Library of Medicine. NCT05983133 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.